nChroma Bio press release
BOSTON Jan. 28, 2026 – nChroma Bio announced that the first patient has been dosed in the company’s Phase 1/2 clinical trial evaluating CRMA-1001, its investigational epigenetic silencer designed to achieve functional cure for chronic hepatitis B virus (HBV) infection.
CRMA-1001 is an optimized next generation epigenetic therapy designed to durably silence viral antigen expression and HBV replication by methylating both covalently closed circular (cccDNA) and integrated HBV DNA (intDNA) without genome cutting. Preclinical data demonstrated robust and durable suppression of hepatitis B surface antigen (HBsAg) and HBV DNA across models, supporting the translational potential of this approach.
Read the full press release here.
Source : nChroma Bio
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.